Your browser doesn't support javascript.
loading
Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs.
Godman, Brian; Malmström, Rickard E; Diogene, Eduardo; Jayathissa, Sisira; McTaggart, Stuart; Cars, Thomas; Alvarez-Madrazo, Samantha; Baumgärtel, Christoph; Brzezinska, Anna; Bucsics, Anna; Campbell, Stephen; Eriksson, Irene; Finlayson, Alexander; Fürst, Jurij; Garuoliene, Kristina; Gutiérrez-Ibarluzea, Iñaki; Hviding, Krystyna; Herholz, Harald; Joppi, Roberta; Kalaba, Marija; Laius, Ott; Malinowska, Kamila; Pedersen, Hanne B; Markovic-Pekovic, Vanda; Piessnegger, Jutta; Selke, Gisbert; Sermet, Catherine; Spillane, Susan; Tomek, Dominik; Voncina, Luka; Vlahovic-Palcevski, Vera; Wale, Janet; Wladysiuk, Magdalena; van Woerkom, Menno; Zara, Corinne; Gustafsson, Lars L.
Afiliação
  • Godman B; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge Stockholm, Sweden ; Medicines Use and Health, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, UK.
  • Malmström RE; Clinical Pharmacology Unit, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Solna Stockholm, Sweden.
  • Diogene E; Clinical Pharmacology Service, Vall d'Hebron University Hospital, Fundació Institut Català de Farmacologia, Autonomous University of Barcelona Barcelona, Spain.
  • Jayathissa S; Department of Medicine, Hutt Valley DHB Lower Hutt, Wellington, New Zealand.
  • McTaggart S; Public Health and Intelligence Business Unit, NHS National Services Scotland Edinburgh, UK.
  • Cars T; Department of Healthcare Development, Public Healthcare Services Committee, Stockholm County Council Stockholm, Sweden ; Department of Medical Sciences, Uppsala University Uppsala, Sweden.
  • Alvarez-Madrazo S; Medicines Use and Health, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde Glasgow, UK.
  • Baumgärtel C; Austrian Medicines and Medical Devices Agency Wien, Austria.
  • Brzezinska A; Agency for Health Technology Assessment Warsaw, Poland.
  • Bucsics A; Department of Finance, Faculty of Business, Economics and Statistics, University of Vienna Vienna, Austria ; Hauptverband der Österreichischen Sozialversicherungsträger Vienna, Austria.
  • Campbell S; Centre for Primary Care, Institute of Population Health, University of Manchester Manchester, UK.
  • Eriksson I; Department of Healthcare Development, Public Healthcare Services Committee, Stockholm County Council Stockholm, Sweden.
  • Finlayson A; Green Templeton College, University of Oxford Oxford, UK.
  • Fürst J; Health Insurance Institute Ljubljana, Slovenia.
  • Garuoliene K; Medicines Reimbursement Department, National Health Insurance Fund Vilnius, Lithuania.
  • Gutiérrez-Ibarluzea I; Basque Office for HTA, Ministry of Health and Consumer Affairs, Basque Government Basque Country, Spain.
  • Hviding K; Norwegian Medicines Agency Oslo, Norway.
  • Herholz H; Kassenärztliche Vereinigung Hessen Frankfurt am Main, Germany.
  • Joppi R; Pharmaceutical Drug Department, Azienda Sanitaria Locale of Verona Verona, Italy.
  • Kalaba M; Department of Medicines and Pharmacoeconomics, Republic Institute for Health Insurance Belgrade, Serbia.
  • Laius O; State Agency of Medicines Tartu, Estonia.
  • Malinowska K; Department of Epidemiology and Health Promotion, Public Health School Warsaw, Poland ; Drug Management Department, National Health Fund Warsaw, Poland.
  • Pedersen HB; Division of Health Systems and Public Health, Health Technologies and Pharmaceuticals, WHO Regional Office for Europe Copenhagen, Denmark.
  • Markovic-Pekovic V; Faculty of Medicine, University of Banja Luka Banja Luka, Bosnia and Herzegovina ; Ministry of Health and Social Welfare Banja Luka, Bosnia and Herzegovina.
  • Piessnegger J; Hauptverband der Österreichischen Sozialversicherungsträger Vienna, Austria.
  • Selke G; Wissenschaftliches Institut der AOK (WidO) Berlin, Germany.
  • Sermet C; IRDES Paris, France.
  • Spillane S; Department of Pharmacology and Therapeutics, Trinity College Dublin Dublin, Ireland.
  • Tomek D; Faculty of Pharmacy, Comenius University and Faculty of Medicine, Slovak Medical University Bratislava, Slovakia.
  • Voncina L; Ministry of Health Zagreb, Croatia.
  • Vlahovic-Palcevski V; Unit for Clinical Pharmacology, University Hospital Rijeka Rijeka, Croatia.
  • Wale J; Independent Consumer Advocate, VIC Melbourne, Australia.
  • Wladysiuk M; HTA Consulting Cracow, Poland.
  • van Woerkom M; Dutch Institute for Rational Use of Medicine Utrecht, Netherlands.
  • Zara C; Barcelona Health Region, Catalan Health Service Barcelona, Spain.
  • Gustafsson LL; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge Stockholm, Sweden.
Front Pharmacol ; 5: 109, 2014.
Article em En | MEDLINE | ID: mdl-24959145
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido